Charles River Laboratories

major US biomedical company

CRL NYSE ISIN US1598641074 SEC CIK 1100682 LEI 5493008S8WYPIT0LWO97
Follow Charles River Laboratories Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $982.7M −2.2% vs same quarter last year
Net income $333.1M +512% vs same quarter last year
EPS, diluted $6.86 +523.6% vs same quarter last year
Operating cash flow $254.1M +18.8% vs same quarter last year
Revenue by quarter
$1B
$984.2M
$1B
$1B
$994.2M
$995.8M
$1B
$982.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$2B$0$2B$4B$6BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$4B−$144.3M
FY24$4B$22.2M
FY23$4.1B$474.6M
FY22$4B$486.2M
FY21$3.5B$391M
FY20$2.9B$364.3M
FY19$2.6B$252M
FY18$2.3B$226.4M
FY17$1.9B$123.4M
FY16$1.7B$154.8M
FY15$1.4B$149.3M
FY14$1.3B$126.7M
FY13$1.2B$102.8M
FY12$1.1B$97.9M
FY11$1.1B$110M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−25%0%25%50%75%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-0.6%−3.6%
FY24-5.6%0.5%
FY23-14.9%11.5%
FY22-16.4%12.2%
FY21-16.7%11%
FY20-14.8%12.5%
FY19-13.4%9.6%
FY18-14.6%10%
FY1784.4%15.5%6.6%
FY1683.5%14.1%9.2%
FY1580.6%15.1%11%
FY1479.5%13.7%9.8%
FY1376.6%13%8.8%
FY1277.2%14.7%8.7%
FY1176.5%15.3%9.6%
Free cash flowOperating cash flow minus capital expenditure
$0$200M$400M$600MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$518.5M
FY24$501.6M
FY23$365.4M
FY22$294.9M
FY21$532M
FY20$380M
FY19$340.4M
FY18$301.1M
FY17$235.6M
FY16$261.6M
FY15$243.6M
FY14$195.2M
FY13$169.9M
FY12$160.5M
FY11$157.7M
Returned to shareholdersDividends paid and shares bought back
$0$100M$200M$300M$400MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$360.7M
FY24$119.2M
FY23$24.2M
FY22$38.7M
FY21$40.7M
FY20$24M
FY19$18.1M
FY18$13.8M
FY17$106.9M
FY16$12.3M
FY15$117.5M
FY14$122M
FY13$165.9M
FY12$64.2M
FY11$283.8M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Charles River Laboratories
  • Healthcare median
−100%−75%−50%−25%0%25%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCharles River LaboratoriesHealthcare median
FY25−3.6%−30.6%
FY240.5%−47%
FY2311.5%−58%
FY2212.2%−80.4%
FY2111%−71.9%
FY2012.5%−62.2%
FY199.6%−46.3%
FY1810%−49.6%
FY176.6%−45.9%
FY169.2%−36%
FY1511%−38.4%
FY149.8%−35.5%
FY138.8%−37.1%
FY128.7%−29.1%
FY119.6%−27.9%